---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-275470"
form_type: "8-K"
ticker: null
cik: "0001834645"
company_name: "Peak Bio, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T15:20:37.706398+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Peak Bio completes SPAC merger; receives Nasdaq delisting notice for low public float

## Summary
- Completed business combination with Ignyte; common stock to trade as PKBO, warrants as PKBOW on Nasdaq from Nov 2, 2022.
- Nasdaq notified company it fails to meet 1,000,000 unrestricted publicly held shares requirement; suspension set for Nov 10 unless hearing requested.
- Entered new PIPE subscription agreements raising $3.025M from 302,500 shares and 281,325 warrants; also converted $1.75M in bridge loans into 176,579 shares and 164,218 warrants.
- Waived closing conditions requiring $7.5M minimum cash and $20M total cash; Chardan withdrew as financial advisor and forfeited $550k fee.

## SEC filing metadata
- accession: 0001193125-22-275470
- form_type: 8-K
- cik: 0001834645
- company_name: Peak Bio, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834645/000119312522275470/0001193125-22-275470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834645/000119312522275470/d391470d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-275470
- JSON: https://secwatch.observer/filing/0001193125-22-275470.json
- Plain text: https://secwatch.observer/filing/0001193125-22-275470.txt

## Key facts
- Listing & Compliance Notices
  Peak Bio, Inc. received a nasdaq deficiency notice notice regarding other (rules IM-5101-2, 5505(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Rules: IM-5101-2, 5505(a)(2)
  source text: November 1, 2022, Peak Bio, Inc. (the “ Company ”) received written notice (the “ Notice ”) from the Staff of the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the Staff has determined that the Company has not complied with the requirements of IM-5101-2 because (i) the Company has not demonstrated that its common stock complies with the minimum 1,000,000 unrestricted publicly held shares requirement in Listing Rule 5505(a)(2) (the “ Unrestricted Publicly Held Shares Requirement ”) and (ii) the Company’s warrants do not qualify for in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834645/000119312522275470/0001193125-22-275470-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.